Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
This grant funds research centers to conduct innovative, translational studies aimed at improving prevention, detection, diagnosis, and treatment of specific or related human cancers, requiring clinical trials.
Browse similar grants
Funder: National Institutes of Health
Due Dates: September 25, 2029 (Closing date for applications)
Funding Amounts: $1,400,000 estimated total program funding; 10 expected awards; no cost sharing or matching required
Summary: Supports investigator-initiated translational research to improve prevention, early detection, diagnosis, and treatment of organ-specific cancers or highly related cancer groups.
Key Information: Clinical trials are required, and SPORE projects must reach a translational human endpoint within the grant project period.
Description
The National Cancer Institute (NCI) invites applications for P50 Research Center Grants through its Specialized Programs of Research Excellence (SPOREs). The program supports state-of-the-art, investigator-initiated translational research aimed at improving prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. Depending on the proposed research, awards may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR).
Supported research must be based on human biology, using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. The emphasis is on translating research toward human endpoints within the grant project period. This clinical-trial-required opportunity, PAR-28-022, covers SPOREs for 2027, 2028, and 2029 and reissues PAR-23-284.
